FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202042235> ?p ?o ?g. }

• W3202042235 abstract "Abstract Background and Objective GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are rare, inherited neurodegenerative disorders with no available symptomatic or disease modifying treatments. This clinical trial aimed to investigate the safety and efficacy of N-acetyl-L-leucine (NALL) on symptoms of pediatric (≥ 6 years) and adult patients with GM2 gangliosidosis. Methods We conducted an 8-center, multi-national, open-label, rater-blinded Phase IIb study (IB1001-201). Patients with a genetically confirmed diagnosis of GM2 gangliosidosis were assessed during a baseline period, a 6-week treatment period (orally administered NALL 4 g/day in patients ≥13 years, weight-tiered doses for patients 6-12 years), and a 6-week post-treatment washout period. The primary Clinical Impression of Change in Severity (CI-CS) endpoint (based on a 7-point Likert scale) was assessed by blinded, centralized raters who compared randomized video pairs of each patient performing a pre-defined primary anchor test (8-Meter Walk Test or 9-Hole Peg Test) during each study periods. Secondary outcomes included cerebellar rating scales (namely Scale for the Assessment and Rating of Ataxia), clinical global impression, and quality of life assessments. Results 30 patients aged 6 to 55 years with a confirmed diagnosis of GM2 gangliosidosis (Tay-Sachs or Sandhoff’s disease) were enrolled. 29 patients were included in the primary modified intention-to-treat analysis. NALL met the CI-CS primary endpoint (mean difference 0.71, SD=2.09, 90% CI 0.00, 1.50, p =0.044), as well as secondary endpoints. No treatment-related serious adverse events occurred. Conclusions This study showed NALL led to a statistically significant improvement in symptoms, functioning, and quality of life in patients with GM2 gangliosidosis. It is a safe, well-tolerated, easily administered oral therapy, therefore offering a favorable risk/benefit profile for this serious, debilitating disorder. NALL is a new therapeutic option for the treatment of this rare disease that has no other approved therapies worldwide. Classification of Evidence This study provides Class IV evidence NALL is safe, well-tolerated, and improves neurological symptoms and quality of life in patients with GM2 gangliosidosis. Trial Registration Information The trial is registered with ClinicalTrials.gov ( NCT03759665 ; registered 30-Nov-2018), EudraCT ( 2018-004406-25 ), and DRKS ( DRKS00017539 ). The first patient was enrolled 07-June-2019." @default.
• W3202042235 created "2021-10-11" @default.
• W3202042235 creator A5022227939 @default.
• W3202042235 creator A5026428280 @default.
• W3202042235 creator A5027633483 @default.
• W3202042235 creator A5029675348 @default.
• W3202042235 creator A5031435836 @default.
• W3202042235 creator A5040729727 @default.
• W3202042235 creator A5042252461 @default.
• W3202042235 creator A5058641127 @default.
• W3202042235 creator A5066632194 @default.
• W3202042235 creator A5076949222 @default.
• W3202042235 creator A5081155368 @default.
• W3202042235 creator A5082051712 @default.
• W3202042235 creator A5091346458 @default.
• W3202042235 date "2021-09-27" @default.
• W3202042235 modified "2023-10-16" @default.
• W3202042235 title "N-acetyl-L-leucine improves symptoms and functioning in GM2 Gangliosidosis (Tay-Sachs & Sandhoff)" @default.
• W3202042235 cites W2083930723 @default.
• W3202042235 cites W2108116414 @default.
• W3202042235 cites W2117257456 @default.
• W3202042235 cites W2129415962 @default.
• W3202042235 cites W2148347826 @default.
• W3202042235 cites W2397368147 @default.
• W3202042235 cites W2462837143 @default.
• W3202042235 cites W2795823005 @default.
• W3202042235 cites W2886544055 @default.
• W3202042235 cites W2917235576 @default.
• W3202042235 cites W2982366500 @default.
• W3202042235 cites W3007100847 @default.
• W3202042235 cites W3015871979 @default.
• W3202042235 cites W3047322234 @default.
• W3202042235 cites W3083346065 @default.
• W3202042235 cites W3092516038 @default.
• W3202042235 cites W3121664580 @default.
• W3202042235 cites W3157386383 @default.
• W3202042235 cites W3188004113 @default.
• W3202042235 cites W3189943578 @default.
• W3202042235 doi "https://doi.org/10.1101/2021.09.24.21264020" @default.
• W3202042235 hasPublicationYear "2021" @default.
• W3202042235 type Work @default.
• W3202042235 sameAs 3202042235 @default.
• W3202042235 citedByCount "2" @default.
• W3202042235 countsByYear W32020422352022 @default.
• W3202042235 countsByYear W32020422352023 @default.
• W3202042235 crossrefType "posted-content" @default.
• W3202042235 hasAuthorship W3202042235A5022227939 @default.
• W3202042235 hasAuthorship W3202042235A5026428280 @default.
• W3202042235 hasAuthorship W3202042235A5027633483 @default.
• W3202042235 hasAuthorship W3202042235A5029675348 @default.
• W3202042235 hasAuthorship W3202042235A5031435836 @default.
• W3202042235 hasAuthorship W3202042235A5040729727 @default.
• W3202042235 hasAuthorship W3202042235A5042252461 @default.
• W3202042235 hasAuthorship W3202042235A5058641127 @default.
• W3202042235 hasAuthorship W3202042235A5066632194 @default.
• W3202042235 hasAuthorship W3202042235A5076949222 @default.
• W3202042235 hasAuthorship W3202042235A5081155368 @default.
• W3202042235 hasAuthorship W3202042235A5082051712 @default.
• W3202042235 hasAuthorship W3202042235A5091346458 @default.
• W3202042235 hasBestOaLocation W32020422351 @default.
• W3202042235 hasConcept C126322002 @default.
• W3202042235 hasConcept C142724271 @default.
• W3202042235 hasConcept C168563851 @default.
• W3202042235 hasConcept C187212893 @default.
• W3202042235 hasConcept C203092338 @default.
• W3202042235 hasConcept C204787440 @default.
• W3202042235 hasConcept C27081682 @default.
• W3202042235 hasConcept C2776000289 @default.
• W3202042235 hasConcept C2777878887 @default.
• W3202042235 hasConcept C2779134260 @default.
• W3202042235 hasConcept C2779390119 @default.
• W3202042235 hasConcept C71924100 @default.
• W3202042235 hasConceptScore W3202042235C126322002 @default.
• W3202042235 hasConceptScore W3202042235C142724271 @default.
• W3202042235 hasConceptScore W3202042235C168563851 @default.
• W3202042235 hasConceptScore W3202042235C187212893 @default.
• W3202042235 hasConceptScore W3202042235C203092338 @default.
• W3202042235 hasConceptScore W3202042235C204787440 @default.
• W3202042235 hasConceptScore W3202042235C27081682 @default.
• W3202042235 hasConceptScore W3202042235C2776000289 @default.
• W3202042235 hasConceptScore W3202042235C2777878887 @default.
• W3202042235 hasConceptScore W3202042235C2779134260 @default.
• W3202042235 hasConceptScore W3202042235C2779390119 @default.
• W3202042235 hasConceptScore W3202042235C71924100 @default.
• W3202042235 hasLocation W32020422351 @default.
• W3202042235 hasOpenAccess W3202042235 @default.
• W3202042235 hasPrimaryLocation W32020422351 @default.
• W3202042235 hasRelatedWork W1602863373 @default.
• W3202042235 hasRelatedWork W1685924513 @default.
• W3202042235 hasRelatedWork W1791773224 @default.
• W3202042235 hasRelatedWork W1973224327 @default.
• W3202042235 hasRelatedWork W1987793436 @default.
• W3202042235 hasRelatedWork W2507057052 @default.
• W3202042235 hasRelatedWork W2608651147 @default.
• W3202042235 hasRelatedWork W2767492078 @default.
• W3202042235 hasRelatedWork W2885330026 @default.
• W3202042235 hasRelatedWork W3202042235 @default.
• W3202042235 isParatext "false" @default.
• W3202042235 isRetracted "false" @default.
• W3202042235 magId "3202042235" @default.

• next